CNMD — CONMED Corporation

Summary of CONMED's Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Sales: $317 million, down 1.3% year-over-year. Excluding the exit from gastroenterology (GI) products, sales increased by 3.8%.
• Adjusted Net Income: $27.1 million, a decrease of 8.5% year-over-year.
• Adjusted Diluted EPS: $0.89, down 6.3% year-over-year.
• Gross Margin: 57.4%, up 100 basis points from the prior year.
• Cash Flow from Operations: $13.5 million, significantly lower than $41.5 million in Q1 2025.
• Long-term Debt: Increased to $860.2 million, with a leverage ratio of 3.1x.
• Share Buybacks: Approximately 858,000 shares repurchased for $37.4 million.

2. Strategic Updates and Business Highlights

• Divestiture of GI Products: CONMED completed agreements to divest its GI product lines to focus on higher growth, higher-margin offerings, including AirSeal, Buffalo Filter, and BioBrace.
• Growth Platforms:
  • AirSeal: Continued growth in robotic and laparoscopic surgery; potential for high single-digit to low double-digit growth.
  • Buffalo Filter: Legislative support for smoke evacuation laws is expected to drive growth; product line transitioning to direct sales.
  • BioBrace: Strong performance in sports medicine, with increasing surgeon adoption and clinical validation.
• Supply Chain Improvements: Enhanced supply chain performance is enabling proactive engagement with customers and supporting growth in the orthopedic segment.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Raised organic growth expectation to 5.0% - 6.5%, with total reported revenue expected between $1.35 billion and $1.375 billion.
• Q2 Revenue Forecast: Anticipated between $336 million and $340 million.
• Adjusted EPS Guidance: Maintained at $4.30 - $4.45 for the full year, despite increased interest expense from debt refinancing.

4. Bad News, Challenges, or Points of Concern

• Sales Decline: Total sales decreased year-over-year, primarily due to the exit from GI products and a decline in general surgery sales, which fell 8.5%.
• Interest Expense Increase: Expected to impact adjusted EPS by at least $0.10 due to the shift from convertible notes to bank debt for refinancing.
• Macro Economic Pressures: Potential inflationary pressures on commodity prices affecting cost of goods sold, though management is working to mitigate these impacts.
• General Surgery Weakness: Continued challenges in the general surgery segment, with significant declines in sales and reliance on non-focused OEM products.

5. Notable Q&A Insights

• Debt Refinancing Strategy: Management is focused on refinancing with bank debt rather than issuing new convertible notes, citing unfavorable market conditions for the latter.
• Laparoscopic Market Potential: AirSeal penetration in the laparoscopic market remains low (6-7%), but management is optimistic about growth opportunities and has seen increased unit placements.
• Buffalo Filter's OEM Business: The OEM segment is a drag on overall sales, but management expects this to diminish as the focus shifts to direct sales.
• Visibility on Legislative Changes: There is potential for additional states to enact smoke evacuation laws, which could further benefit Buffalo Filter’s growth.

Overall, CONMED is navigating challenges from its divestiture and macroeconomic pressures while focusing on strategic growth platforms and improving operational efficiencies.